Suraksha Diagnostic Limited (NSE:SURAKSHA)

Market Cap	18.60B +11.7%
Revenue (ttm)	3.47B +25.6%
Net Income	418.21M +31.0%
EPS	8.03 +32.5%
Shares Out	52.08M
PE Ratio	44.48
Forward PE	42.60
Dividend	0.50 (0.14%)
Ex-Dividend Date	Sep 15, 2026

Volume	1,747,468
Open	354.00
Previous Close	350.40
Day's Range	328.95 - 384.00
52-Week Range	224.10 - 384.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About Suraksha Diagnostic

Suraksha Diagnostic Limited provides pathological and radiological services through diagnostic centers in India. It offers home collection services; pathology services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, haematology, clinical biochemistry and immunology, immunohistochemistry, fluorescence in-situ hybridization, cytogenetics, flow cytometry, newborn screening, and NGS. The company also provides microarray, QF-PCR, FISH, karyotyping, and NIPT services; X-Ray, MRI scan, CT scan, US...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1992
• Employees: 1,600
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SURAKSHA

Financial Performance

In fiscal year 2026, Suraksha Diagnostic's revenue was 3.10 billion, an increase of 23.13% compared to the previous year's 2.52 billion. Earnings were 321.87 million, an increase of 1.14%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error